Title	Total Patient Population
Number of Patients Screened	44
Number of Patients Enrolled	44
Number of Patients Evaluable for Toxicity	44
Number of Patients Evaluated for Efficacy	44
Evaluation Method	RECIST 1.1
Response Assessment CR	n = 0 (0%)
Response Assessment PR	n = 7 (15.9%)
Response Assessment SD	n = 17 (38.6%)
Response Assessment PD	n = 20 (45.5%)
Response Assessment OTHER	n = 0 (0%)
(Median) Duration Assessments PFS	110 days, CI: 65.0–155.0
(Median) Duration Assessments OS	367 days, CI: 310.4–423.6
Waterfall plot legend	Waterfall plot of evaluable patients (n = 44) showing the largest decrease in the sum of the target lesions compared with baseline.
Outcome Notes	There were no complete responses; ORR was 15.9%, and the disease control rate was 54.5%.